AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 35320999 — intervention group
Group type: COMPARATOR
Intervention: Routine nursing in cardiology (Control)
Number of subjects: 170
Study 32102807 — intervention group
Group type: EXPERIMENTAL
Intervention: narrative text messages plus financial incentive for 12 months (SMS+I)
Number of subjects: 105
Study 32102807 — intervention group
Group type: EXPERIMENTAL
Intervention: narrative text messages for 12 months (SMS only)
Number of subjects: 105
Study 32102807 — intervention group
Group type: COMPARATOR
Intervention: waiting list control
Number of subjects: 105
Study 35343114 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-session relapse prevention (RP) program
Number of subjects: 48
Study 35343114 — intervention group
Group type: COMPARATOR
Intervention: 12-session psychoeducation (PE) program
Number of subjects: 48
Study 35343114 — intervention group
Group type: EXPERIMENTAL
Intervention: Both RP and PE groups
Number of subjects: 48
Study 33648579 — intervention group
Group type: COMPARATOR
Intervention: Not applicable (no intervention reported)
Number of subjects: 173
Study 35329004 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine third trimester ultrasonography at 28–30 and 34–36 weeks’ gestation
Number of subjects: 12974
Study 35329004 — intervention group
Group type: COMPARATOR
Intervention: Usual care (selective ultrasonography)
Number of subjects: 12974
Study 32209650 — intervention group
Group type: EXPERIMENTAL
Intervention: eptinezumab 100 mg
Number of subjects: 1072
Study 32209650 — intervention group
Group type: EXPERIMENTAL
Intervention: eptinezumab 300 mg
Number of subjects: 1072
Study 32209650 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 1072
Study 34579077 — intervention group
Group type: EXPERIMENTAL
Intervention: Meal Replacement (MR)
Number of subjects: 50
Study 34579077 — intervention group
Group type: COMPARATOR
Intervention: Dietary Advice (DA)
Number of subjects: 50
Study 33296347 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral melatonin 3mg
Number of subjects: 80
Study 33296347 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 35894099 — intervention group
Group type: COMPARATOR
Intervention: Combination HIV prevention modalities
Number of subjects: 0
Study 35894099 — intervention group
Group type: EXPERIMENTAL
Intervention: Booster vaccine effects on SARS-CoV-2 variants
Number of subjects: 0
Study 34060609 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep convolutional neural network (GSU-Net) for automated segmentation of the sellar region
Number of subjects: 163
Study 34060609 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep convolutional neural network (GSU-Net) for predicting tumor consistency
Number of subjects: 163
Study 34060609 — intervention group
Group type: EXPERIMENTAL
Intervention: Automatic segmentation methods
Number of subjects: 163
Study 33472438 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 (60,000 IU/week) plus standard treatment for 3 months
Number of subjects: 42
Study 33652263 — intervention group
Group type: EXPERIMENTAL
Intervention: Fragility Index (FI) of trials supporting drug approvals
Number of subjects: 81
Study 33652263 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients who withdrew consent or were lost to follow-up
Number of subjects: 81
Study 33652263 — intervention group
Group type: EXPERIMENTAL
Intervention: FI compared to patients who withdrew consent or were lost to follow-up
Number of subjects: 81
Study 33652263 — intervention group
Group type: EXPERIMENTAL
Intervention: Time trend of FI
Number of subjects: 81
Study 33652263 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall survival as primary endpoint
Number of subjects: 81
Study 33652263 — intervention group
Group type: EXPERIMENTAL
Intervention: Palliative setting trials
Number of subjects: 81
Study 33652263 — intervention group
Group type: EXPERIMENTAL
Intervention: Trial sample size and duration of follow-up
Number of subjects: 81
Study 32545057 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron Folic Acid (IFA)
Number of subjects: 19
Study 32545057 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimicronutrient (MMN)
Number of subjects: 19
Study 35060229 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical triple combination (TXA 5% + OXZ 1.5% + BMT 0.33%) applied on the right side of the face
Number of subjects: 40
Study 35060229 — intervention group
Group type: COMPARATOR
Intervention: Topical lipocream (placebo) applied on the left side of the face
Number of subjects: 40
Study 34509684 — intervention group
Group type: EXPERIMENTAL
Intervention: 9% HFA + Silane
Number of subjects: 60
Study 34509684 — intervention group
Group type: EXPERIMENTAL
Intervention: Silane only
Number of subjects: 60
Study 34509684 — intervention group
Group type: EXPERIMENTAL
Intervention: Airborne particle (50 µm)
Number of subjects: 60
Study 34509684 — intervention group
Group type: EXPERIMENTAL
Intervention: Photodynamic therapy (PDT)
Number of subjects: 60
Study 34509684 — intervention group
Group type: EXPERIMENTAL
Intervention: MBP
Number of subjects: 60
Study 34509684 — intervention group
Group type: COMPARATOR
Intervention: No treatment (Control)
Number of subjects: 60
Study 32090655 — intervention group
Group type: EXPERIMENTAL
Intervention: Seeding with nodes high on in-degree centrality and/or inverse constraint
Number of subjects: 0
Study 32090655 — intervention group
Group type: EXPERIMENTAL
Intervention: Random networks
Number of subjects: 0
Study 32090655 — intervention group
Group type: EXPERIMENTAL
Intervention: Uniform threshold distribution
Number of subjects: 0
Study 32090655 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta 7,14 threshold distribution
Number of subjects: 0
Study 32090655 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher threshold standard deviations
Number of subjects: 0
Study 35301726 — intervention group
Group type: EXPERIMENTAL
Intervention: CTI ablation using 400 gs FTI lesions (FTI400 group, n=26)
Number of subjects: 50
Study 35301726 — intervention group
Group type: EXPERIMENTAL
Intervention: CTI ablation using 600 gs FTI lesions (FTI600 group, n=24)
Number of subjects: 50
Study 35301726 — intervention group
Group type: EXPERIMENTAL
Intervention: Total population (not achieving first-pass CTI block)
Number of subjects: 50
Study 32563116 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief Negotiated Interview (BNI)
Number of subjects: 61
Study 32563116 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing (MOTIV)
Number of subjects: 61
Study 32563116 — intervention group
Group type: COMPARATOR
Intervention: No Brief Intervention (no BI)
Number of subjects: 61
Study 35083951 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous tirofiban
Number of subjects: 930
Study 35083951 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 930
Study 32536329 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening for stroke using a structured questionnaire and neurological evaluation by stroke neurologists.
Number of subjects: 2156
Study 32536329 — intervention group
Group type: EXPERIMENTAL
Intervention: Confirmed cases of stroke (41 cases).
Number of subjects: 2156
Study 32536329 — intervention group
Group type: EXPERIMENTAL
Intervention: Assessment of vascular risk factors in stroke survivors.
Number of subjects: 2156
Study 35522470 — intervention group
Group type: EXPERIMENTAL
Intervention: Web drama video series
Number of subjects: 300
Study 35522470 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 300
Study 34930459 — intervention group
Group type: EXPERIMENTAL
Intervention: Olyset® Plus (permethrin and piperonyl butoxide treated LLIN)
Number of subjects: 0
Study 34930459 — intervention group
Group type: COMPARATOR
Intervention: Olyset® Net (permethrin treated LLIN)
Number of subjects: 0
Study 36394843 — intervention group
Group type: EXPERIMENTAL
Intervention: SAF312 (2.5%)
Number of subjects: 24
Study 36394843 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 24
Study 32170033 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous azithromycin 20 mg/kg every 24 hours for 3 days
Number of subjects: 121
Study 32170033 — intervention group
Group type: COMPARATOR
Intervention: Placebo (D5W) every 24 hours for 3 days
Number of subjects: 121
Study 33156279 — intervention group
Group type: EXPERIMENTAL
Intervention: PLICS score system
Number of subjects: 354
Study 33156279 — intervention group
Group type: EXPERIMENTAL
Intervention: PLICS score system with PLICS score ≥7
Number of subjects: 354
Study 33156279 — intervention group
Group type: EXPERIMENTAL
Intervention: PLICS score >7 or 7 with unstable lateral mass fractures
Number of subjects: 354
Study 32270176 — intervention group
Group type: EXPERIMENTAL
Intervention: Esketamine nasal spray (twice weekly during induction, then weekly or every other week during optimization/maintenance)
Number of subjects: 580
Study 32270176 — intervention group
Group type: EXPERIMENTAL
Intervention: Esketamine nasal spray (reduced from weekly to every other week)
Number of subjects: 580
Study 32270176 — intervention group
Group type: EXPERIMENTAL
Intervention: Esketamine nasal spray (increased from every other week to weekly)
Number of subjects: 580
Study 35588898 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-facilitated catheter-directed thrombolysis plus anticoagulation
Number of subjects: 406
Study 35588898 — intervention group
Group type: COMPARATOR
Intervention: Anticoagulation alone
Number of subjects: 406
Study 32535591 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent lifestyle intervention over 8 months
Number of subjects: 97
Study 32535591 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 97
Study 35422167 — intervention group
Group type: EXPERIMENTAL
Intervention: Supine PCNL
Number of subjects: 7
Study 35422167 — intervention group
Group type: COMPARATOR
Intervention: Standard prone PCNL
Number of subjects: 7
Study 32441171 — intervention group
Group type: EXPERIMENTAL
Intervention: Rehydration for 10 minutes in 0.9% saline solution
Number of subjects: 40
Study 32441171 — intervention group
Group type: EXPERIMENTAL
Intervention: Rehydration for 30 minutes in 0.9% saline solution
Number of subjects: 40
Study 32441171 — intervention group
Group type: EXPERIMENTAL
Intervention: Rehydration for 60 minutes in 0.9% saline solution
Number of subjects: 40
Study 32441171 — intervention group
Group type: COMPARATOR
Intervention: Untreated control (no rehydration)
Number of subjects: 40
Study 32441171 — intervention group
Group type: EXPERIMENTAL
Intervention: Rehydrated CP vs. non-rehydrated CP in patients
Number of subjects: 40
Study 32100373 — intervention group
Group type: EXPERIMENTAL
Intervention: Long day (LD; 16 L:8 D)
Number of subjects: 120
Study 32100373 — intervention group
Group type: COMPARATOR
Intervention: Short day (SD; 8 L:16 D)
Number of subjects: 120
Study 32100373 — intervention group
Group type: COMPARATOR
Intervention: Control (CTR; 12.5 L:11.5 D)
Number of subjects: 120
Study 36410582 — intervention group
Group type: EXPERIMENTAL
Intervention: Filtek Bulk Fill Posterior Restorative
Number of subjects: 60
Study 36410582 — intervention group
Group type: COMPARATOR
Intervention: Filtek Supreme XTE Universal Restorative
Number of subjects: 60
Study 33568510 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 doses of DNA GTU-MultiHIV B at week 0, 4, and 12, followed by 2 doses of LIPO-5 vaccine at week 20 and 24
Number of subjects: 103
Study 33568510 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 103
Study 32935748 — intervention group
Group type: EXPERIMENTAL
Intervention: DIY lambda-cyhalothrin LLIN
Number of subjects: 21
Study 32935748 — intervention group
Group type: EXPERIMENTAL
Intervention: Deltamethrin LLIN
Number of subjects: 21
Study 32935748 — intervention group
Group type: COMPARATOR
Intervention: Untreated nets (control)
Number of subjects: 21
Study 33737522 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone (MP)
Number of subjects: 32
Study 33011734 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung-Protective Ventilation (LPV)
Number of subjects: 71
Study 33011734 — intervention group
Group type: COMPARATOR
Intervention: Conventional Mechanical Ventilation (MV)
Number of subjects: 71
Study 34912835 — intervention group
Group type: EXPERIMENTAL
Intervention: Baduanjin exercise for 12 weeks
Number of subjects: 70
Study 34912835 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 70
Study 33516464 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary supplementation of Bupleurum falcatum L saikosaponins (80 mg/kg of diet)
Number of subjects: 480
Study 33516464 — intervention group
Group type: COMPARATOR
Intervention: Control group (no dietary supplementation of saikosaponins)
Number of subjects: 480
Study 32057375 — intervention group
Group type: EXPERIMENTAL
Intervention: Women with PAD
Number of subjects: 13885
Study 33557610 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasoalveolar Molding (NAM)
Number of subjects: 30
Study 33557610 — intervention group
Group type: COMPARATOR
Intervention: Computer-Aided Design NAM (CAD/NAM)
Number of subjects: 30
Study 33462904 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual care plus application of uncoated paper on the sacral area for 5 days
Number of subjects: 135
Study 33462904 — intervention group
Group type: COMPARATOR
Intervention: Usual care only
Number of subjects: 135
Study 33036662 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginger-based herbal tablets (Vomigone ®) at a dose of 1000 mg three times a day for seven days
Number of subjects: 84
Study 33036662 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment for COVID-19 along with Vomigone-like placebo tablets
Number of subjects: 84
Study 33036662 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginger-based herbal tablets (Vomigone ®)
Number of subjects: 84
Study 35984871 — intervention group
Group type: EXPERIMENTAL
Intervention: Ashwagandha (700 mg daily, full spectrum extract of ASH root)
Number of subjects: 60
Study 35984871 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 60
Study 33509667 — intervention group
Group type: EXPERIMENTAL
Intervention: 21.6 g/day Biotis™ GOS (containing 15.0 g/day GOS)
Number of subjects: 44
Study 33509667 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 32553820 — intervention group
Group type: EXPERIMENTAL
Intervention: HEARTBiT blood test for excluding acute cellular rejection (ACR)
Number of subjects: 1622
Study 32553820 — intervention group
Group type: COMPARATOR
Intervention: AlloMap (CareDx, Brisbane, CA)
Number of subjects: 1622
Study 32985777 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behaviour therapy for health anxiety (CBT-HA)
Number of subjects: 444
Study 32985777 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 444
Study 33004018 — intervention group
Group type: EXPERIMENTAL
Intervention: EFIC enrollment
Number of subjects: 169
Study 33004018 — intervention group
Group type: EXPERIMENTAL
Intervention: Disclosure of positive PAMPer study outcome
Number of subjects: 169
Study 33004018 — intervention group
Group type: EXPERIMENTAL
Intervention: Disclosure of hypothetical negative study outcome
Number of subjects: 169
Study 35213904 — intervention group
Group type: EXPERIMENTAL
Intervention: Early treatment (rectal ibuprofen or intravenous acetaminophen)
Number of subjects: 208
Study 35213904 — intervention group
Group type: COMPARATOR
Intervention: Expectant management
Number of subjects: 208
Study 35213904 — intervention group
Group type: EXPERIMENTAL
Intervention: Early treatment
Number of subjects: 208
Study 32677051 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine (single intravenous dose)
Number of subjects: 68
Study 32216168 — intervention group
Group type: EXPERIMENTAL
Intervention: Dissolvable nasal dressing (foam) applied to the olfactory cleft
Number of subjects: 30
Study 36267766 — intervention group
Group type: EXPERIMENTAL
Intervention: Kai Hou Jian (2.5 mL via transoral atomization twice daily for 1 week)
Number of subjects: 86
Study 36267766 — intervention group
Group type: COMPARATOR
Intervention: Budesonide (1 mg nebulization twice daily for 1 week)
Number of subjects: 86
Study 34004226 — intervention group
Group type: EXPERIMENTAL
Intervention: S. salivarius DB‐B5 at 10 billion CFU/day for 4 weeks
Number of subjects: 100
Study 34004226 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 35054027 — intervention group
Group type: EXPERIMENTAL
Intervention: ANI-guided remifentanil administration
Number of subjects: 80
Study 35054027 — intervention group
Group type: COMPARATOR
Intervention: Standard management of remifentanil
Number of subjects: 80
Study 32945735 — intervention group
Group type: EXPERIMENTAL
Intervention: Dried cranberry powder (500 mg)
Number of subjects: 98
Study 32945735 — intervention group
Group type: COMPARATOR
Intervention: Placebo (500 mg)
Number of subjects: 98
Study 33895361 — intervention group
Group type: EXPERIMENTAL
Intervention: Switch to peginterferon-alpha2b (1.5 μg/kg/weekly) for 48 weeks
Number of subjects: 253
Study 33895361 — intervention group
Group type: EXPERIMENTAL
Intervention: Add-on peginterferon-alpha2b (1.5 μg/kg/weekly) for 48 weeks
Number of subjects: 253
Study 33895361 — intervention group
Group type: COMPARATOR
Intervention: Continued nucleoside analogues (controls)
Number of subjects: 253
Study 33895361 — intervention group
Group type: EXPERIMENTAL
Intervention: Switch to peginterferon-alpha2b
Number of subjects: 253
Study 33895361 — intervention group
Group type: EXPERIMENTAL
Intervention: Add-on peginterferon-alpha2b
Number of subjects: 253
Study 33895361 — intervention group
Group type: EXPERIMENTAL
Intervention: Peginterferon treatment
Number of subjects: 253
Study 33276811 — intervention group
Group type: EXPERIMENTAL
Intervention: Ixekizumab (80 mg/ml, 160 mg as a single hypodermic injection) with antiviral therapy (α‐interferon, lopinavir/ritonavir, chloroquine, ribavirin, or arbidol)
Number of subjects: 43
Study 33276811 — intervention group
Group type: COMPARATOR
Intervention: Antiviral therapy alone (same scheme as in stage 1)
Number of subjects: 43
Study 36097674 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabotegravir + rilpivirine LA injections after a 1-month oral lead-in
Number of subjects: 102
Study 36097674 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabotegravir + rilpivirine LA injections
Number of subjects: 102
Study 32152512 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent tube feeding
Number of subjects: 78
Study 32152512 — intervention group
Group type: COMPARATOR
Intervention: Continuous tube feeding
Number of subjects: 78
Study 36433813 — intervention group
Group type: EXPERIMENTAL
Intervention: Video counseling (VC)
Number of subjects: 30
Study 36433813 — intervention group
Group type: COMPARATOR
Intervention: Conventional counseling (CC)
Number of subjects: 30
Study 33340084 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed implant‐supported prostheses (FP)
Number of subjects: 96
Study 33340084 — intervention group
Group type: COMPARATOR
Intervention: Removable implant‐supported prostheses (RP)
Number of subjects: 96
Study 33340084 — intervention group
Group type: COMPARATOR
Intervention: Conventional total prostheses (CP)
Number of subjects: 96
Study 32536023 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 g 2’FL/LNnT
Number of subjects: 60
Study 32536023 — intervention group
Group type: COMPARATOR
Intervention: Placebo (glucose)
Number of subjects: 60
Study 32536023 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 g 2’FL/LNnT
Number of subjects: 60
Study 36301546 — intervention group
Group type: EXPERIMENTAL
Intervention: Mentorship and portable rent subsidies
Number of subjects: 24
Study 36301546 — intervention group
Group type: COMPARATOR
Intervention: No mentorship and portable rent subsidies
Number of subjects: 24
Study 36301546 — intervention group
Group type: EXPERIMENTAL
Intervention: Informal mentors
Number of subjects: 24
Study 33904615 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive feedback (self-esteem boost)
Number of subjects: 0
Study 33904615 — intervention group
Group type: COMPARATOR
Intervention: No feedback (control group)
Number of subjects: 0
Study 33089598 — intervention group
Group type: EXPERIMENTAL
Intervention: Esomeprazole 40 mg bid
Number of subjects: 207
Study 33089598 — intervention group
Group type: COMPARATOR
Intervention: Esomeprazole 20 mg bid
Number of subjects: 207
Study 33089598 — intervention group
Group type: EXPERIMENTAL
Intervention: Eradication-successful patients
Number of subjects: 207
Study 33089598 — intervention group
Group type: COMPARATOR
Intervention: Eradication-failed patients
Number of subjects: 207
Study 32708343 — intervention group
Group type: EXPERIMENTAL
Intervention: Artificial Intelligence (AI) in endoscopic assessment
Number of subjects: 0
Study 32708343 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-assisted diagnostic systems
Number of subjects: 0
Study 32708343 — intervention group
Group type: EXPERIMENTAL
Intervention: Machine learning systems
Number of subjects: 0
Study 32708343 — intervention group
Group type: EXPERIMENTAL
Intervention: AI systems
Number of subjects: 0
Study 35321918 — intervention group
Group type: EXPERIMENTAL
Intervention: Prone positioning (lying on stomach)
Number of subjects: 248
Study 35321918 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (no instruction to adopt prone position)
Number of subjects: 248
Study 35321918 — intervention group
Group type: EXPERIMENTAL
Intervention: Prone positioning
Number of subjects: 248
Study 35321918 — intervention group
Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 248
Study 34579785 — intervention group
Group type: EXPERIMENTAL
Intervention: ED-dispensing of ICS with home and school supervision
Number of subjects: 13
Study 34579785 — intervention group
Group type: COMPARATOR
Intervention: ED-dispensing of ICS with home supervision
Number of subjects: 13
Study 34579785 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall participant retention
Number of subjects: 13
Study 36229147 — intervention group
Group type: EXPERIMENTAL
Intervention: ECCE programme
Number of subjects: 3240
Study 33910549 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Cognitive Therapy for Children (MBCT-C)
Number of subjects: 10
Study 32387091 — intervention group
Group type: EXPERIMENTAL
Intervention: apoB
Number of subjects: 0
Study 32387091 — intervention group
Group type: COMPARATOR
Intervention: LDL-C/non-HDL-C
Number of subjects: 0
Study 36170581 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional physical therapy combined with pulsed local cryotherapy three times per week for 12 weeks
Number of subjects: 40
Study 36170581 — intervention group
Group type: COMPARATOR
Intervention: Traditional physical therapy three times per week for 12 weeks
Number of subjects: 40
Study 34977251 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25% ropivacaine
Number of subjects: 60
Study 34977251 — intervention group
Group type: COMPARATOR
Intervention: 0.5% ropivacaine
Number of subjects: 60